Darolutamide

达罗他胺

Report date: 2026/05/28 20:00:21
NME

Base Information

Drug NameDarolutamide
Drug Alias Name达罗他胺片DarramamideNubeqa诺倍戈BAY-1841788 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAndrogen Receptor antagonists
TargetsAndrogen Receptor
Therapy Area/IndicationsCastration-Sensitive Prostate NeoplasmsHormone-Sensitive Prostate NeoplasmsRenal Insufficiency +[9] 
Global Approved IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Approved Indications in ChinaProstatic Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2019/07/30
Country/TerritoryCzechiaBelgiumBulgaria +[48] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesOrion Corp
China Registration ClassN/A

Develop Information

Active CompaniesD'Or Institute For Research And EducationOrion Corp Orion Pharma EspooSwiss Cancer Institute +[12] 
Inactive CompaniesSwiss Group for Clinical Cancer Research (SAKK)
Active IndicationsCastration-Sensitive Prostate NeoplasmsHormone-Sensitive Prostate NeoplasmsArthritis, Psoriatic +[5] 
Inactive IndicationsRenal InsufficiencyHepatic InsufficiencyBreast Neoplasms +[4] 

Other Information

ATC CodeL02BB06
Related LinksWikipediaDrugBankKEGG